Patterns of Medication Use During Pregnancy in Rheumatoid Arthritis

Harvard School of Public Health, Boston, Massachusetts, USA.
Arthritis care & research 05/2011; 63(5):721-8. DOI: 10.1002/acr.20422
Source: PubMed


To characterize therapies prescribed during pregnancy to women with rheumatoid arthritis (RA).
We conducted a cohort study of women with RA with pregnancies using health care utilization data from 2002-2008. We examined the distribution of RA drugs by therapeutic classes, including nonsteroidal antiinflammatory drugs (NSAIDs)/coxibs, glucocorticoids, nonbiologic disease-modifying antirheumatic drugs (DMARDs), and biologic DMARDs, during 90-day pregnancy trimesters and the 180 days prior to pregnancy. Drugs were characterized according to the Food and Drug Administration risk classification system. Differences in exposure by period were determined by chi-square tests.
A total of 393 pregnancies were identified among 34,169 women with RA. Seventy-two percent of pregnancies ended in a delivery. Approximately 24% of women with RA received a DMARD during preconception. At any point during pregnancy, 23% of women with deliveries were dispensed ≥1 DMARD and the proportion of use declined from the first to the third trimester (P = 0.03). Similar to DMARD therapy, use of NSAIDs/coxibs and exposure to category D/X medications were significantly lower compared to prepregnancy use (P < 0.05). In contrast, more women were prescribed glucocorticoids during pregnancy than before pregnancy. Use of biologics occurred in 12.5% of pregnancies. Compared to women with deliveries, women who experienced abortions were more frequently exposed to NSAIDs/coxibs (P < 0.05). Dispensing of category D/X medications was also higher in women with spontaneous abortions and primarily involved methotrexate (P < 0.05).
Approximately 24% of women with RA received a DMARD in the 180 days before conception, and the proportion dropped during pregnancy. Glucocorticoid use remained high throughout pregnancy. Our results suggest that continued efforts directed at counseling women and their physicians about the potential risks/benefits of RA therapies during pregnancy are warranted.

7 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The present work reviews the available data on rheumatoid arthritis (RA) during pregnancy and the postpartum period. The data generally support some improvement in RA during pregnancy, but these data are not consistent, and a subgroup of patients may have significant disability and flares. The literature supports a tendency toward postpartum flares. Babies born to mothers with RA are found to have lower birth weight, intrauterine growth restriction, and an increased risk of delivery by cesarean section. Limited safety information is available for medications used for treatment during pregnancy and lactation. There are many options for treatment during the first trimester and throughout pregnancy, but each decision must be made on an individual basis. Whereas methotrexate and leflunomide are contraindicated in pregnancy, sulfasalazine is generally considered useful, as is hydroxychloroquine (despite the latter's FDA pregnancy category C rating). Of the biologics, the tumor necrosis factor (TNFi) are classified as category B; the other biologics vary between categories B and C, but more human data are available on TNFi. Drug Dev Res 72:689–702, 2011. © 2011 Wiley Periodicals, Inc.
    Drug Development Research 12/2011; 72(8). DOI:10.1002/ddr.20478 · 0.77 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To elaborate recommendations for the treatment of rheumatoid arthritis in Brazil. Literature review with articles' selection based on evidence and the expert opinion of the Rheumatoid Arthritis Committee of the Brazilian Society of Rheumatology. 1) The therapeutic decision should be shared with the patient; 2) immediately after the diagnosis, a disease-modifying antirheumatic drug (DMARD) should be prescribed, and the treatment adjusted to achieve remission; 3) treatment should be conducted by a rheumatologist; 4) the initial treatment includes synthetic DMARDs; 5) methotrexate is the drug of choice; 6) patients who fail to respond after two schedules of synthetic DMARDs should be assessed for the use of biologic DMARDs; 7) exceptionally, biologic DMARDs can be considered earlier; 8) anti-TNF agents are preferentially recommended as the initial biologic therapy; 9) after therapeutic failure of a first biologic DMARD, other biologics can be used; 10) cyclophosphamide and azathioprine can be used in severe extra-articular manifestations; 11) oral corticoid is recommended at low doses and for short periods of time; 12) non-steroidal anti-inflammatory drugs should always be prescribed in association with a DMARD; 13) clinical assessments should be performed on a monthly basis at the beginning of treatment; 14) physical therapy, rehabilitation, and occupational therapy are indicated; 15) surgical treatment is recommended to correct sequelae; 16) alternative therapy does not replace traditional therapy; 17) family planning is recommended; 18) the active search and management of comorbidities are recommended; 19) the patient's vaccination status should be recorded and updated; 20) endemic-epidemic transmissible diseases should be investigated and treated.
    Revista Brasileira de Reumatologia 04/2012; 52(2):152-74. DOI:10.1590/S0482-50042012000200002 · 1.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Teratogenic medications are commonly prescribed to women of reproductive age. Caring for women who may benefit from the use of teratogenic medications requires clinicians to engage patients in shared decision-making on the risks and benefits of medication use in the context of the patient's fertility goals, the implications of the patient's medical condition for a pregnancy and the risks and benefits of various contraceptive methods. Effective communication about all of these issues is essential to avoiding medication-induced birth defects. However, data suggest that such communication remains inadequate, leading some women to face unintentional exposure of a pregnancy to a teratogen, undesired pregnancy or, sometimes, the need for pregnancy termination services. This review outlines key information needed to ensure safe prescribing to women of childbearing age. It includes recommendations for changes in medical education, healthcare delivery and health policy to facilitate thoughtful prescribing and comprehensive care.
    Women s Health 07/2012; 8(4):415-25. DOI:10.2217/whe.12.25
Show more

Preview (2 Sources)

7 Reads
Available from